One Enzyme Damages Neurons in ALS, FTD, and Alzheimer's Alike
A Harvard study finds a common DNA-damaging mechanism — driven by topoisomerase 1 — lurking across three major neurodegenerative diseases.
Summary
Researchers at Harvard sequenced the genomes of 469 individual neurons from brains affected by ALS, frontotemporal dementia (FTD), Alzheimer's disease, and healthy controls. They discovered that neurons in all three diseases accumulate far more somatic mutations than healthy neurons, and that a specific pattern of small DNA insertions and deletions — resembling damage caused by the enzyme topoisomerase 1 (TOP1) — was found in 22–76% of diseased neurons but only 2% of control neurons. Laboratory assays confirmed that TOP1 becomes abnormally stuck to DNA in these diseases, creating persistent damage. This finding is striking because ALS/FTD and Alzheimer's involve different toxic proteins (TDP-43 and tau respectively), yet they appear to share this underlying genomic vulnerability — suggesting TOP1 inhibition could be a novel therapeutic target across multiple devastating brain diseases.
Detailed Summary
Neurodegenerative diseases like ALS, frontotemporal dementia (FTD), and Alzheimer's disease (AD) collectively affect tens of millions of people worldwide, yet the precise mechanisms that kill neurons remain poorly understood. A major new study published in Cell by researchers from Boston Children's Hospital and Harvard Medical School reveals a surprisingly shared genomic vulnerability across these conditions — an enzyme called topoisomerase 1 (TOP1) that goes rogue and inflicts lasting DNA damage on neurons.
The team performed single-cell whole-genome sequencing on 469 individual neurons isolated from post-mortem brain tissue of patients with C9ORF72-linked ALS, C9ORF72-linked FTD, Alzheimer's disease, and neurologically healthy controls. This approach allowed them to catalogue somatic mutations — DNA changes that accumulate in individual cells over a lifetime — at unprecedented resolution in human brain tissue.
The results were striking. Neurons from all three diseases showed elevated somatic single-nucleotide variants and small insertions and deletions (indels) compared to controls. A mutational signature analysis pinpointed a specific indel pattern — resembling the known signature ID4 — affecting 22% of ALS neurons, 76% of FTD neurons, and 61% of AD neurons, versus just 2% of control neurons. This pattern is consistent with TOP1-mediated mutagenesis, where the enzyme becomes covalently trapped on DNA rather than completing its normal strand-cutting and rejoining cycle.
To validate this mechanism, the researchers used RADAR assays to directly detect TOP1-DNA covalent complexes in diseased tissue, confirming that TOP1 trapping is genuinely elevated. Duplex sequencing further identified single-strand DNA events as likely precursor lesions preceding the observed indels.
The implications are profound. ALS/FTD and Alzheimer's are driven by different pathological proteins — TDP-43 and tau respectively — yet both appear to trigger the same genomic damage pathway. This convergence suggests TOP1-associated genome instability could be a shared downstream mechanism of neuronal death, and potentially a common therapeutic target. Limitations include that the full paper was unavailable for review; this summary is based on the abstract only.
Key Findings
- TOP1-mediated DNA indel damage found in 22% of ALS, 76% of FTD, and 61% of AD neurons versus only 2% of controls.
- Single-cell sequencing of 469 neurons confirmed elevated somatic mutations across all three neurodegenerative diseases.
- RADAR assays directly confirmed TOP1-DNA covalent complexes are abnormally increased in diseased brain tissue.
- ALS/FTD and Alzheimer's — driven by different proteins — share a common mechanism of neuronal genomic instability.
- Single-strand DNA breaks identified as likely precursor lesions, pointing to an early, potentially targetable step in neurodegeneration.
Methodology
Researchers performed single-cell whole-genome sequencing of 469 post-mortem neurons from C9ORF72 ALS, C9ORF72 FTD, Alzheimer's disease, and healthy control brains. Mutational signature analysis, RADAR assays for TOP1-DNA complex detection, and duplex sequencing were used to characterize and validate the genomic damage patterns.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible; finer methodological details, statistical thresholds, and nuances of the findings cannot be assessed. The study uses post-mortem tissue, which cannot establish whether TOP1 damage is a cause or consequence of neurodegeneration. Findings are limited to C9ORF72-linked ALS and FTD and late-onset Alzheimer's; generalizability to other genetic subtypes requires further study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: